MVA-BN® Measles
Recombinant MVA-BN® based measles vaccine
A Phase I clinical study in healthy adults revealed that
Bavarian Nordic's vaccine candidate was highly immunogenic in
subjects that had prior measles immunity. Comparison of these
results to another vaccination study performed by Bavarian Nordic
in which adult subjects with existing measles immunity were
vaccinated with a current licensed measles vaccine, revealed that
Bavarian Nordic's measles vaccine construct was capable of inducing
much better measles immune responses than the licensed measles
vaccine. This information suggests that Bavarian Nordic's vaccine
construct has a high potential to overcome the weaknesses of
current measles vaccines. Maternally derived antibodies will not
affect the efficacy of the vaccine and the vaccine may induce
effective immune responses in very young children with immature
immune systems.
The first paediatric clinical trial evaluating the safety and
immunogenicity of MVA-BN® Measles has been initiated as planned
in the second quarter of 2009. Ninety children between the ages on
6 months to 6 years will be vaccinated in this Phase I/II study.
The first children have been vaccinated, without any reported
safety concerns.
This study is planned to be followed by a pivotal proof of
concept study in children younger than 12 months. The clinical
development of the measles candidate vaccine is planned to
demonstrate that an MVA-BN® based vaccine is not only safe, but
also capable of inducing strong immune responses in the very young,
which will support the childhood platform concept for
MVA-BN®.
